亚速逊对一组凝血试验的影响

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis Pub Date : 2025-07-01 DOI:10.1016/j.rpth.2025.102950

Julie Vassart , Diane Bangoup Ndzatou , Marie Didembourg , Laure Morimont , Clotilde Brisbois , Laurent Jamart , Fabian Demeure , Aurélien Lebreton , François Mullier , Julien Favresse , Michaël Hardy , Jean-Michel Dogné , Jonathan Douxfils

{"title":"亚速逊对一组凝血试验的影响","authors":"Julie Vassart , Diane Bangoup Ndzatou , Marie Didembourg , Laure Morimont , Clotilde Brisbois , Laurent Jamart , Fabian Demeure , Aurélien Lebreton , François Mullier , Julien Favresse , Michaël Hardy , Jean-Michel Dogné , Jonathan Douxfils","doi":"10.1016/j.rpth.2025.102950","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>During the last few years, the small, oral, activated factor XI inhibitor, asundexian, has been investigated in different cardiovascular disorders. However, little is known about its impact on laboratory coagulation assays.</div></div><div><h3>Objectives</h3><div>To describe the effects of asundexian on a panel of laboratory coagulation assays.</div></div><div><h3>Methods</h3><div>The following assays were performed in normal pooled plasma spiked with increasing concentrations of asundexian (0-2000 ng/mL): activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen quantification (PT-derived and Clauss method), one-stage aPTT and PT-based coagulation factor assays, chronometric protein C and immunoturbidimetric protein S assays, reptilase time, chromogenic ecarin assay, dilute Russell’s viper venom time assays, thrombin generation assay initiated by tissue factor (1, 5, and 20 pM) and ellagic acid (0.42 μM), rotational thromboelastometry intrinsically- and extrinsically-triggered assays, kaolin-activated clotting time, and glass bead-activated clotting time. This latter assay was also carried out in whole blood.</div></div><div><h3>Results</h3><div>Asundexian up to 2000 ng/mL impacted aPTT and one-stage aPTT-based coagulation factor assays, with high variability between reagents and methodologies. Asundexian reduced thrombin generation triggered by ellagic acid and 1 or 5 pM tissue factor. The rotational thromboelastometry intrinsically-triggered assays and kaolin- and glass bead-activated clotting time assays were affected by asundexian 2000 ng/mL, while overall, no significant interference was observed with any of the remaining assays.</div></div><div><h3>Conclusion</h3><div>Despite this study including a comprehensive panel of coagulation assays, asundexian may still affect other coagulation assays not assessed here. Further investigations in patients treated with asundexian are therefore warranted.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 5","pages":"Article 102950"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of asundexian on a panel of coagulation assays\",\"authors\":\"Julie Vassart , Diane Bangoup Ndzatou , Marie Didembourg , Laure Morimont , Clotilde Brisbois , Laurent Jamart , Fabian Demeure , Aurélien Lebreton , François Mullier , Julien Favresse , Michaël Hardy , Jean-Michel Dogné , Jonathan Douxfils\",\"doi\":\"10.1016/j.rpth.2025.102950\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>During the last few years, the small, oral, activated factor XI inhibitor, asundexian, has been investigated in different cardiovascular disorders. However, little is known about its impact on laboratory coagulation assays.</div></div><div><h3>Objectives</h3><div>To describe the effects of asundexian on a panel of laboratory coagulation assays.</div></div><div><h3>Methods</h3><div>The following assays were performed in normal pooled plasma spiked with increasing concentrations of asundexian (0-2000 ng/mL): activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen quantification (PT-derived and Clauss method), one-stage aPTT and PT-based coagulation factor assays, chronometric protein C and immunoturbidimetric protein S assays, reptilase time, chromogenic ecarin assay, dilute Russell’s viper venom time assays, thrombin generation assay initiated by tissue factor (1, 5, and 20 pM) and ellagic acid (0.42 μM), rotational thromboelastometry intrinsically- and extrinsically-triggered assays, kaolin-activated clotting time, and glass bead-activated clotting time. This latter assay was also carried out in whole blood.</div></div><div><h3>Results</h3><div>Asundexian up to 2000 ng/mL impacted aPTT and one-stage aPTT-based coagulation factor assays, with high variability between reagents and methodologies. Asundexian reduced thrombin generation triggered by ellagic acid and 1 or 5 pM tissue factor. The rotational thromboelastometry intrinsically-triggered assays and kaolin- and glass bead-activated clotting time assays were affected by asundexian 2000 ng/mL, while overall, no significant interference was observed with any of the remaining assays.</div></div><div><h3>Conclusion</h3><div>Despite this study including a comprehensive panel of coagulation assays, asundexian may still affect other coagulation assays not assessed here. Further investigations in patients treated with asundexian are therefore warranted.</div></div>\",\"PeriodicalId\":20893,\"journal\":{\"name\":\"Research and Practice in Thrombosis and Haemostasis\",\"volume\":\"9 5\",\"pages\":\"Article 102950\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research and Practice in Thrombosis and Haemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2475037925002742\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037925002742","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在过去的几年里，小的，口服的，激活因子XI抑制剂，assundexian，已经在不同的心血管疾病中进行了研究。然而，它对实验室凝血分析的影响知之甚少。目的探讨亚散地仙对一组实验室凝血试验的影响。方法在正常血浆中加入一定量的亚砜（0 ~ 2000 ng/mL），进行以下实验：活化部分凝血活素时间（aPTT）、凝血酶原时间（PT）、纤维蛋白原定量（PT衍生法和Clauss法）、单阶段aPTT和基于PT的凝血因子测定、计时蛋白C和免疫比浊蛋白S测定、爬行酶时间、显色癌蛋白测定、稀释罗素毒蛇毒液时间测定、组织因子（1、5和20 pM）和花藻酸（0.42 μM）启动的凝血酶生成测定、旋转血栓弹性测定内在和外部触发的测定，高岭土活化的凝血时间，和玻璃珠活化的凝血时间。后一种测定也在全血中进行。结果asdexian高达2000 ng/mL影响aPTT和基于aPTT的一期凝血因子测定，且试剂和方法之间存在很大差异。由鞣花酸和1或5 pM组织因子引起的凝血酶生成的亚松地性减少。旋转血栓弹性测定固有触发的测定和高岭土和玻璃球激活的凝血时间测定受到2000 ng/mL的影响，而总体而言，没有观察到对任何其他测定的显著干扰。结论：尽管这项研究包括了一组全面的凝血试验，但asundexian仍可能影响其他未被评估的凝血试验。因此，有必要对接受阿森地安治疗的患者进行进一步调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of asundexian on a panel of coagulation assays

Background

During the last few years, the small, oral, activated factor XI inhibitor, asundexian, has been investigated in different cardiovascular disorders. However, little is known about its impact on laboratory coagulation assays.

Objectives

To describe the effects of asundexian on a panel of laboratory coagulation assays.

Methods

The following assays were performed in normal pooled plasma spiked with increasing concentrations of asundexian (0-2000 ng/mL): activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen quantification (PT-derived and Clauss method), one-stage aPTT and PT-based coagulation factor assays, chronometric protein C and immunoturbidimetric protein S assays, reptilase time, chromogenic ecarin assay, dilute Russell’s viper venom time assays, thrombin generation assay initiated by tissue factor (1, 5, and 20 pM) and ellagic acid (0.42 μM), rotational thromboelastometry intrinsically- and extrinsically-triggered assays, kaolin-activated clotting time, and glass bead-activated clotting time. This latter assay was also carried out in whole blood.

Results

Asundexian up to 2000 ng/mL impacted aPTT and one-stage aPTT-based coagulation factor assays, with high variability between reagents and methodologies. Asundexian reduced thrombin generation triggered by ellagic acid and 1 or 5 pM tissue factor. The rotational thromboelastometry intrinsically-triggered assays and kaolin- and glass bead-activated clotting time assays were affected by asundexian 2000 ng/mL, while overall, no significant interference was observed with any of the remaining assays.

Conclusion

Despite this study including a comprehensive panel of coagulation assays, asundexian may still affect other coagulation assays not assessed here. Further investigations in patients treated with asundexian are therefore warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊